Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Biosimilars: The future of treating breast cancer

Justin Stebbing • 2 Jun 2017
ASCO 2017
Breast Cancer Trastuzumab

Justin Stebbing, MD, PhD, from Imperial College Healthcare NHS Trust, London, UK talks to us about the findings from a Phase III trial designed to compare the effect of a trastuzumab biosimilar, SB3, to herceptin, in treating HER2-positive breast cancer. He reports a complete response observed in patients receiving the biosimilar without any increase in toxicity, as compared to herceptin-treated patients and adds that adding the biosimilar into the treatment regimen for breast cancer in the future would be desirable due to its cheaper cost and few adverse events reported from its use. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

More from Justin Stebbing

The importance of HCPs feeling comfortable and confident with biosimilars
1:38
The importance of HCPs feeling comfortable and confident with biosimilars
Justin Stebbing • 19 Oct 2018
Education is key to improve confidence in biosimilars
1:27
Education is key to improve confidence in biosimilars
Justin Stebbing • 19 Oct 2018
Positive results for trastuzumab biosimilar CT-P6 in HER2+ early breast cancer
2:33
Positive results for trastuzumab biosimilar CT-P6 in HER2+ early breast cancer
Justin Stebbing • 19 Oct 2018
Developments in PD-1 and PD-L1 inhibitors presented at ASCO 2016
2:10
Developments in PD-1 and PD-L1 inhibitors presented at ASCO 2016
Justin Stebbing • 3 Jun 2016

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals